Drug
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution
Netarsudil 0.02%/latanoprost 0.005% fixed dose combination ophthalmic solution is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 1 completed trials
Completion Rate
100%(1/1)
Active Trials
1(33%)
Results Posted
100%(1 trials)
Phase Distribution
Ph phase_4
2
67%
Phase Distribution
0
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
2(100.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
1 of 1 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(2)
Completed(1)
Detailed Status
Completed1
Enrolling by invitation1
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Phase 42 (100.0%)
Trials by Status
completed133%
enrolling_by_invitation133%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_4
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
NCT07325240
enrolling_by_invitation
The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)
NCT06960629
completedphase_4
Rocklatan® Evaluation
NCT05283395
Clinical Trials (3)
Showing 3 of 3 trials
NCT07325240Phase 4
24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients
NCT06960629
The Effect of ROCK Inhibitors on Corneas of Patients With Glaucoma and Pseudophakic Bullous Keratopathy (PBK)
NCT05283395Phase 4
Rocklatan® Evaluation
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3